NasdaqGM - Delayed Quote USD

Skye Bioscience, Inc. (SKYE)

13.00 +0.15 (+1.17%)
At close: April 26 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Punit S. Dhillon B.A. Executive Chairman, President, CEO & Secretary 720k -- 1980
Ms. Kaitlyn Melanie Arsenault CPA Chief Financial Officer 476k -- 1987
Dr. Christopher G. Twitty Ph.D. Chief Scientific Officer -- -- 1973
Mr. Tu Diep M.Sc. Chief Development Officer -- -- 1981

Skye Bioscience, Inc.

11250 El Camino Real
Suite 100
San Diego, CA 92130
United States
858 410 0266 https://skyebioscience.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
11

Description

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapeutic drugs that modulate the endocannabinoid system. The company's lead clinical program's product candidate is nimacimab, a peripherally-restricted negative allosteric modulating antibody specific for the human cannabinoid receptor 1 (CB1) receptor, administered as a subcutaneous injectable that is Phase II clinical trials for the treatment of metabolic disorders, including obesity. It is also developing SBI-100 Ophthalmic Emulsion,a CB1 agonist that is Phase II clinical trials for the treatment of glaucoma and ocular hypertension. It has licensing agreement with Tautomer Bioscience, (Pty) Limited to develop and commercialize SBI-100; and collaborative research agreement with VivaCell Biotechnology Espana, S.L.U for the research and development of SBI-200 and the preclinical development services for novel derivatives. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Corporate Governance

Skye Bioscience, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Apr 24, 2024
    POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing
    See Full Filing
  • Apr 04, 2024
    S-1/A: Offering Registrations
    See Full Filing
  • Apr 03, 2024
    8-K: Corporate Changes & Voting Matters
    See Full Filing
  • Mar 27, 2024
    S-1: Offering Registrations
    See Full Filing
  • Mar 22, 2024
    10-K: Periodic Financial Reports
    See Full Filing

Upcoming Events

May 12, 2024 - May 16, 2024
Skye Bioscience, Inc. Earnings Call

Related Tickers

SLNO Soleno Therapeutics, Inc.
37.89
+1.47%
 
JANX Janux Therapeutics, Inc.
47.39
+0.62%
 
KURA Kura Oncology, Inc.
19.65
+3.42%
 
NUVL Nuvalent, Inc.
66.86
+1.20%
 
NUVB Nuvation Bio Inc.
2.6800
+2.29%
 
LBPH Longboard Pharmaceuticals, Inc.
19.72
+2.44%
 
CTNM Contineum Therapeutics, Inc.
15.72
-1.69%
 
KRRO Korro Bio, Inc.
62.93
+7.52%
 
CGEM Cullinan Therapeutics, Inc.
25.30
+31.43%
 
VIGL Vigil Neuroscience, Inc.
2.7100
+5.04%